RHO and ovarian carcinoma: Similarly, pre-treatment with Y-27632 or overexpression of a dominant-negative mutant of Rho inhibited lysophosphatidic acid (LPA) proteolytic enzyme expression and invasiveness of ovarian cancer (CAOV-3, PA-1) cells [173].